High-dose I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan.

Clicks: 325
ID: 101525
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #3 of 4 articles by views in annals of nuclear medicine

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
The aim of the study was to investigate the outcomes and prognostic factors of high-dose I-metaiodobenzylguanidine (I-MIBG) therapy in patients with refractory or relapsed neuroblastoma (NBL) in Japan.We retrospectively analyzed 20 patients with refractory or relapsed high-risk NBL who underwent I-MIBG therapy with an administration dose ranging from 444 to 666 MBq/kg at Kanazawa University Hospital, Japan, between September 2008 and September 2013. We focused on measurements regarding their initial responses, prognostic factors, survivals, and toxicities following I-MIBG therapy using our hospital data and questionnaires from the hospitals that these patients were initially referred from. Furthermore, we performed Kaplan-Meier survival analysis to evaluate event-free survival (EFS) and overall survival (OS).In 19 patients with complete follow-up data, the median age at first I-MIBG treatment was 7.9 years (range 2.5-17.7 years). Following I-MIBG therapy, 17 of the 19 patients underwent stem-cell transplantations, and their treatment response was either complete (CR) or partial (PR) in three and two cases, respectively. The EFS and OS rates at 1 year following I-MIBG therapy were 42% and 58%, respectively, and those at 5 years following I-MIBG therapy were 16% and 42%, respectively. Using the two-sample log-rank test, the OS time following I-MIBG therapy was significantly longer for < 3-year time interval between the initial diagnosis and I-MIBG therapy (p = 0.017), Curie score < 16 just before I-MIBG therapy (p = 0.002), without pain (p = 0.002), without both vanillylmandelic acid (VMA) and homovanillic acid (HVA) elevation (p = 0.037) at I-MIBG therapy, and with CR or PR following I-MIBG therapy (p = 0.015). Although severe hematological toxicities were identified in all 19 patients, severe nonhematological toxicity was not recorded in any patient, except for one patient with grade 3 anorexia and nausea.High-dose I-MIBG therapy in patients with refractory or relapsed high-risk NBL can provide a favorable prognosis without severe nonhematological toxicities. Better prognosis may be anticipated in patients with the initial good response, no pain at I-MIBG therapy, no VMA and HVA elevation at I-MIBG therapy, low Curie score (< 16) just before I-MIBG therapy, and short time interval (< 3 years) between the initial diagnosis and I-MIBG therapy.
Reference Key
kayano2020highdoseannals Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal annals of nuclear medicine
Year 2020
DOI
10.1007/s12149-020-01460-z
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.